Letrozole Combination Increases PFS In ER+ and HER2-Negative Breast Cancer
Afinitor Significantly Reduced Tumor Size In TSC-Related Renal Angiomyolipomas
Nexavar Improves PFS In Phase III Trial
Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease
Ibrutinib Produces 68% Overall Response Rate in Phase II Trial
Researchers Uncover Tumors Sensitive to Chemotherapy
Researchers Find Genetic Alterations in Triple-Negative Cancers Following Treatment
Existing HER2 Drugs May Help More In Breast Cancer Treatment
Smoking Intensity and Markers Predict Cancer Aggressiveness
Low Adiponcetin Hormone Levels Linked to Increased Cancer Risk
No Difference in Toxicity Between IMRT and PRT In Medicare Patients
NCI CTEP Approved Trials For the Month of January
FDA Expands Gleevec Indication For Children with Ph+ ALL
Trending Stories
- Charles Rudin named cancer center director at MSK
- Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- FDA’s acting drug chief, acting vaccines chief, and chief of staff ousted in the wake of Makary departure
- Marcel van den Brink: Microbiome research is now in “critical phase” where evidence points to therapeutic use
- NCI’s Letai gets softball questions from Senate appropriators at an otherwise contentious hearing
